1.Association between atherogenic index of plasma trajectory and new-onset coronary heart disease in Chinese elderly people: a prospective cohort study.
Wan-Li HU ; Yv-Lin CHENG ; Dong-Hai SU ; Yv-Fang CUI ; Zi-Hao LI ; Ge-Fei LI ; Hai-Yun GAO ; Da-Tian GAO ; Xiao-Ke ZHANG ; Song-He SHI
Journal of Geriatric Cardiology 2025;22(10):835-843
BACKGROUND:
The atherogenic index of plasma (AIP) has been shown to be positively correlated with cardiovascular disease in previous studies. However, it is unclear whether elderly people with long-term high AIP levels are more likely to develop coronary heart disease (CHD). Therefore, the aim of this study was to investigate the relationship between AIP trajectory and CHD incidence in elderly people.
METHODS:
19,194 participants aged ≥ 60 years who had three AIP measurements between 2018 and 2020 were included in this study. AIP was defined as log10 (triglyceride/high-density lipoprotein cholesterol). The group-based trajectory model was used to identify different trajectory patterns of AIP from 2018 to 2020. Cox proportional hazards models were used to estimate the hazard ratio (HR) with 95% CI of CHD events between different trajectory groups from 2020 to 2023.
RESULTS:
Three different trajectory patterns were identified through group-based trajectory model: the low-level group (n = 7410, mean AIP: -0.25 to -0.17), the medium-level group (n = 9981, mean AIP: 0.02-0.08), and the high-level group (n = 1803, mean AIP: 0.38-0.42). During a mean follow-up of 2.65 years, a total of 1391 participants developed CHD. After adjusting for potential confounders, compared with the participants in the low-level group, the HR with 95% CI of the medium-level group and the high-level group were estimated to be 1.24 (1.10-1.40) and 1.43 (1.19-1.73), respectively. These findings remained consistent in subgroup analyses and sensitivity analyses.
CONCLUSIONS
There was a significant correlation between persistent high AIP level and increased CHD risk in the elderly. This suggests that monitoring the long-term changes in AIP is helpful to identify individuals at high CHD risk in elderly people.
2.Zedoarondiol Inhibits Neovascularization in Atherosclerotic Plaques of ApoE-/- Mice by Reducing Platelet Exosomes-Derived MiR-let-7a.
Bei-Li XIE ; Bo-Ce SONG ; Ming-Wang LIU ; Wei WEN ; Yu-Xin YAN ; Meng-Jie GAO ; Lu-Lian JIANG ; Zhi-Die JIN ; Lin YANG ; Jian-Gang LIU ; Da-Zhuo SHI ; Fu-Hai ZHAO
Chinese journal of integrative medicine 2025;31(3):228-239
OBJECTIVE:
To investigate the effect of zedoarondiol on neovascularization of atherosclerotic (AS) plaque by exosomes experiment.
METHODS:
ApoE-/- mice were fed with high-fat diet to establish AS model and treated with high- and low-dose (10, 5 mg/kg daily) of zedoarondiol, respectively. After 14 weeks, the expressions of anti-angiogenic protein thrombospondin 1 (THBS-1) and its receptor CD36 in plaques, as well as platelet activation rate and exosome-derived miR-let-7a were detected. Then, zedoarondiol was used to intervene in platelets in vitro, and miR-let-7a was detected in platelet-derived exosomes (Pexo). Finally, human umbilical vein endothelial cells (HUVECs) were transfected with miR-let-7a mimics and treated with Pexo to observe the effect of miR-let-7a in Pexo on tube formation.
RESULTS:
Animal experiments showed that after treating with zedoarondiol, the neovascularization density in plaques of AS mice was significantly reduced, THBS-1 and CD36 increased, the platelet activation rate was markedly reduced, and the miR-let-7a level in Pexo was reduced (P<0.01). In vitro experiments, the platelet activation rate and miR-let-7a levels in Pexo were significantly reduced after zedoarondiol's intervention. Cell experiments showed that after Pexo's intervention, the tube length increased, and the transfection of miR-let-7a minics further increased the tube length of cells, while reducing the expressions of THBS-1 and CD36.
CONCLUSION
Zedoarondiol has the effect of inhibiting neovascularization within plaque in AS mice, and its mechanism may be potentially related to inhibiting platelet activation and reducing the Pexo-derived miRNA-let-7a level.
Animals
;
MicroRNAs/genetics*
;
Exosomes/drug effects*
;
Plaque, Atherosclerotic/genetics*
;
Neovascularization, Pathologic/genetics*
;
Human Umbilical Vein Endothelial Cells/metabolism*
;
Humans
;
Blood Platelets/drug effects*
;
Apolipoproteins E/deficiency*
;
Thrombospondin 1/metabolism*
;
CD36 Antigens/metabolism*
;
Platelet Activation/drug effects*
;
Male
;
Mice
;
Mice, Inbred C57BL
3.Analysis of prognostic risk factors for intracranial solitary fibrous tumor/hemangiopericytoma
Da LIN ; Hongbing ZHANG ; Song HAN ; Fangjun LIU
Chinese Journal of Postgraduates of Medicine 2025;48(7):654-659
Objective:To analyze the risk factors of prognosis in patients with intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).Methods:The clinical data of 74 intracranial SFT/HPC patients underwent surgical treatment from January 2017 to January 2024 in Luhe Hospital, Capital Medical University and Sanbo Brain Hospital, Capital Medical University were retrospectively analyzed. The patients were followed up the prognosis (including recurrence, death and extracranial metastasis). Kaplan-Meier and log-rank tests were used to analyze the risk factors of prognosis in patients with intracranial SFT/HPC, and multivariate Cox analysis was used to analyze the independent risk factors of prognosis in patients with intracranial SFT/HPC.Results:Seventy-four patients with intracranial SFT/HPC were followed up for 3 to 80 months, averaging 52.5 months. Among them, there were 17 cases of recurrence, 6 cases of extracranial metastasis, and 12 cases of death. In patients with intracranial SFT/HPC, the results of the log-rank univariate analysis showed that the tumor location, resection extent, WHO pathological grade, and adjuvant radiotherapy were risk factors of recurrence ( P<0.01); the tumor location, WHO pathological grade and extracranial metastasis were risk factors of death ( P<0.05 or <0.01); and the age, WHO pathological grade and Ki67 were risk factors of extracranial metastasis ( P<0.05 or <0.01). In patients with intracranial SFT/HPC, multivariate Cox regression analysis result showed that the subtotal resection and non-postoperative radiation therapy were independent risk factors of recurrence ( HR = 0.377 and 0.315, 95% CI 0.148 to 0.932 and 0.164 to 2.221, P<0.01 and <0.05); the WHO pathological grade Ⅲ and extracranial metastasis were independent risk factors of death ( HR = 3.657 and 1.657, 95% CI 0.964 to 7.147 and 0.964 to 2.848, P<0.01); the WHO pathological grade Ⅲ was an independent risk factor of extracranial metastasis ( HR = 1.657, 95% CI 0.964 to 2.848, P<0.01). Conclusions:Patients with intracranial SFT/HPC who undergo subtotal resection and non-postoperative radiation therapy are more prone to recurrence, WHO pathological grade Ⅲ patients are more likely to develop extracranial metastases, and extracranial metastases patients have shorter survival. For intracranial SFT/HPC patients with pathologically high-grade, SFT/HPC, it is necessary to increase the frequency of follow-ups and be alert for extracranial metastasis.
4.Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture-dislocation in adults (version 2025)
Qingde WANG ; Tongwei CHU ; Jian DONG ; Liangjie DU ; Haoyu FENG ; Shunwu FAN ; Shiqing FENG ; Yanzheng GAO ; Yong HAI ; Da HE ; Dianming JIANG ; Jianyuan JIANG ; Bin LIN ; Bin LIU ; Baoge LIU ; Fang LI ; Feng LI ; Li LI ; Weishi LI ; Fangcai LI ; Xiaoguang LIU ; Hongjian LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Xuhua LU ; Keya MAO ; Xuexiao MA ; Yong QIU ; Limin RONG ; Jun SHU ; Yueming SONG ; Tiansheng SUN ; Yan WANG ; Zhe WANG ; Zheng WANG ; Bing WANG ; Linfeng WANG ; Yu WANG ; Qinghe WANG ; Jigong WU ; Hong XIA ; Guoyong YIN ; Jinglong YAN ; Wen YUAN ; Yong YANG ; Qiang YANG ; Cao YANG ; Jie ZHAO ; Jianguo ZHANG ; Yue ZHU ; Zezhang ZHU ; Yingjie ZHOU ; Zhongmin ZHANG ; Yan ZENG ; Dingjun HAO ; Baorong HE ; Wei MEI
Chinese Journal of Trauma 2025;41(3):243-252
Cervical spinal cord injury without fracture-dislocation (CSCIWFD) is referred to as a special type of cervical spinal cord injury characterized by traumatic spinal cord dysfunction and no significant bony structural abnormalities on imagines. Duo to the high risk of missed diagnosis during the initial consultation, CSCIWFD may lead to progressive neurological deterioration or even complete paralysis, severely impacting patients′ prognosis. Currently, there are no established consensuses over the diagnosis and treatment of CSCIWFD, such as the lack of evidence-based standards for indications of non-surgical treatment and risk of secondary neurological injury, as well as debates over the optimal timing for surgical intervention and indications for different surgical approaches. To address these issues, the Spine Trauma Group of the Orthopedic Branch of the Chinese Medical Doctor Association organized experts in the relevant fields to formulate Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture- dislocation in adults ( version 2025) . Based on evidence-based medicine and the principles of scientific rigor and clinical applicability, the guidelines proposed 11 recommendations covering terminology, diagnosis, evaluation treatment, and rehabilitation, etc., aiming to standardize the management of CSCIWFD.
5.Analysis of prognostic risk factors for intracranial solitary fibrous tumor/hemangiopericytoma
Da LIN ; Hongbing ZHANG ; Song HAN ; Fangjun LIU
Chinese Journal of Postgraduates of Medicine 2025;48(7):654-659
Objective:To analyze the risk factors of prognosis in patients with intracranial solitary fibrous tumor/hemangiopericytoma (SFT/HPC).Methods:The clinical data of 74 intracranial SFT/HPC patients underwent surgical treatment from January 2017 to January 2024 in Luhe Hospital, Capital Medical University and Sanbo Brain Hospital, Capital Medical University were retrospectively analyzed. The patients were followed up the prognosis (including recurrence, death and extracranial metastasis). Kaplan-Meier and log-rank tests were used to analyze the risk factors of prognosis in patients with intracranial SFT/HPC, and multivariate Cox analysis was used to analyze the independent risk factors of prognosis in patients with intracranial SFT/HPC.Results:Seventy-four patients with intracranial SFT/HPC were followed up for 3 to 80 months, averaging 52.5 months. Among them, there were 17 cases of recurrence, 6 cases of extracranial metastasis, and 12 cases of death. In patients with intracranial SFT/HPC, the results of the log-rank univariate analysis showed that the tumor location, resection extent, WHO pathological grade, and adjuvant radiotherapy were risk factors of recurrence ( P<0.01); the tumor location, WHO pathological grade and extracranial metastasis were risk factors of death ( P<0.05 or <0.01); and the age, WHO pathological grade and Ki67 were risk factors of extracranial metastasis ( P<0.05 or <0.01). In patients with intracranial SFT/HPC, multivariate Cox regression analysis result showed that the subtotal resection and non-postoperative radiation therapy were independent risk factors of recurrence ( HR = 0.377 and 0.315, 95% CI 0.148 to 0.932 and 0.164 to 2.221, P<0.01 and <0.05); the WHO pathological grade Ⅲ and extracranial metastasis were independent risk factors of death ( HR = 3.657 and 1.657, 95% CI 0.964 to 7.147 and 0.964 to 2.848, P<0.01); the WHO pathological grade Ⅲ was an independent risk factor of extracranial metastasis ( HR = 1.657, 95% CI 0.964 to 2.848, P<0.01). Conclusions:Patients with intracranial SFT/HPC who undergo subtotal resection and non-postoperative radiation therapy are more prone to recurrence, WHO pathological grade Ⅲ patients are more likely to develop extracranial metastases, and extracranial metastases patients have shorter survival. For intracranial SFT/HPC patients with pathologically high-grade, SFT/HPC, it is necessary to increase the frequency of follow-ups and be alert for extracranial metastasis.
6.Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture-dislocation in adults (version 2025)
Qingde WANG ; Tongwei CHU ; Jian DONG ; Liangjie DU ; Haoyu FENG ; Shunwu FAN ; Shiqing FENG ; Yanzheng GAO ; Yong HAI ; Da HE ; Dianming JIANG ; Jianyuan JIANG ; Bin LIN ; Bin LIU ; Baoge LIU ; Fang LI ; Feng LI ; Li LI ; Weishi LI ; Fangcai LI ; Xiaoguang LIU ; Hongjian LIU ; Yong LIU ; Zhongjun LIU ; Shibao LU ; Xuhua LU ; Keya MAO ; Xuexiao MA ; Yong QIU ; Limin RONG ; Jun SHU ; Yueming SONG ; Tiansheng SUN ; Yan WANG ; Zhe WANG ; Zheng WANG ; Bing WANG ; Linfeng WANG ; Yu WANG ; Qinghe WANG ; Jigong WU ; Hong XIA ; Guoyong YIN ; Jinglong YAN ; Wen YUAN ; Yong YANG ; Qiang YANG ; Cao YANG ; Jie ZHAO ; Jianguo ZHANG ; Yue ZHU ; Zezhang ZHU ; Yingjie ZHOU ; Zhongmin ZHANG ; Yan ZENG ; Dingjun HAO ; Baorong HE ; Wei MEI
Chinese Journal of Trauma 2025;41(3):243-252
Cervical spinal cord injury without fracture-dislocation (CSCIWFD) is referred to as a special type of cervical spinal cord injury characterized by traumatic spinal cord dysfunction and no significant bony structural abnormalities on imagines. Duo to the high risk of missed diagnosis during the initial consultation, CSCIWFD may lead to progressive neurological deterioration or even complete paralysis, severely impacting patients′ prognosis. Currently, there are no established consensuses over the diagnosis and treatment of CSCIWFD, such as the lack of evidence-based standards for indications of non-surgical treatment and risk of secondary neurological injury, as well as debates over the optimal timing for surgical intervention and indications for different surgical approaches. To address these issues, the Spine Trauma Group of the Orthopedic Branch of the Chinese Medical Doctor Association organized experts in the relevant fields to formulate Diagnosis and treatment guideline for acute cervical spinal cord injury without fracture- dislocation in adults ( version 2025) . Based on evidence-based medicine and the principles of scientific rigor and clinical applicability, the guidelines proposed 11 recommendations covering terminology, diagnosis, evaluation treatment, and rehabilitation, etc., aiming to standardize the management of CSCIWFD.
7.Role of paeoniflorin in the treatment of diabetes based on network pharmacology and molecular docking
Si-Yao SONG ; Peng LU ; Ding-Xiao WU ; Da KANG ; Yu-Hui HE ; Ying LÜ ; Yan LIN
The Chinese Journal of Clinical Pharmacology 2024;40(15):2261-2264
Objective To explore the potential mechanism of action of paeoniflorin in diabetes mellitus,the related targets and pathways were preliminarily discussed,based on the network pharmacology and molecular docking technology.Methods Analyze the potential targets of paeoniflorin using the Swiss Target Prediction database.Genecards and OMIM databases yielded the genes of diabetes-related illnesses.After taking the intersection of the two,protein-protein interaction network(PPI)was established using STRING and Cytoscape programs to search for key genes with strong correlation and complete gene ontology(GO)and Kyoto Encyclopedia of Genes and Genomes(KEGG)enrichment analysis.Use AutoDockTools and Pymol programs to complete protein molecule docking validation.Results The pharmacologically-related study revealed 63 targets associated with paeoniflorin,4 758 genes related to diabetes,and 50 intersection targets.15 key genes including vascular endothelial growth factor A(VEGFA),epidermal growth factor receptor(EGFR),V-Ha-ras harvey(HRAS),V-src sarcoma(SRC)and heat shock protein hs 90-alpha(HSP90AA1)were screened.RAs-associated protein 1,Ras,calcium and other signaling pathways were obtained by KEGG pathway analysis.Molecular docking results showed that paeoniflorin had good binding ability with key genes.Conclusion Paeoniflorin can treat diabetes through multiple targets and pathways,and this mechanism can provide a basis for the application of paeoniflorin in anti diabetes and drug research and development.
8.Establishment and effect evaluation of multidisciplinary team-based blood glucose management model with the participation of clinical pharmacists in a hospital
Lin CONG ; Fang SONG ; Da WANG ; Yi LU
Journal of Shenyang Medical College 2024;26(4):389-392,448
Objective:To establish a multidisciplinary team-based blood glucose management model with the participation of clinical pharmacists,and to evaluate the effect of this model on blood glucose management in hospitalized patients.Methods:A clinical pharmacists involved multidisciplinary team-based blood glucose management model was built to manage the blood glucose of inpatients.A total of 45 patients were employed and randomly divided into two groups,including common management group and multidisciplinary team-based management group.The fasting and 2-hour postprandial blood glucose levels at the fifth day after treatment,the length of hospital stay,adverse events,and medication compliance within 2 months after discharge between the two groups were compared.Results:The fasting blood glucose of the study group after 5 d treatment had no significant difference with the control group(P>0.05).The 2-hour postprandial blood glucose of the study group was significantly lower and closer to the target level than that of the control group(P<0.05).The length of hospital stay in the study group was significantly shorter than that in the control group,and the medication compliance within 2 months after discharge was significantly higher than that in the control group(P<0.05).There was no significant difference in adverse events between the two groups(P>0.05).Conclusion:The clinical pharmacists involved multidisciplinary team-based blood glucose management model has a definite effect on the blood glucose management of inpatients,including accelerating blood glucose attainment,effectively shortening the length of hospital stay,and significantly improving the medication compliance of inpatients.
9.Evaluation of Microsphere-based xMAP Test for gyrA Mutation Identification in Mycobacterium Tuberculosis.
Xi Chao OU ; Bing ZHAO ; Ze Xuan SONG ; Shao Jun PEI ; Sheng Fen WANG ; Wen Cong HE ; Chun Fa LIU ; Dong Xin LIU ; Rui Da XING ; Hui XIA ; Yan Lin ZHAO
Biomedical and Environmental Sciences 2023;36(4):384-387
10.HbA1c comparison and diagnostic efficacy analysis of multi center different glycosylated hemoglobin detection systems.
Ping LI ; Ying WU ; Yan XIE ; Feng CHEN ; Shao qiang CHEN ; Yun Hao LI ; Qing Qing LU ; Jing LI ; Yong Wei LI ; Dong Xu PEI ; Ya Jun CHEN ; Hui CHEN ; Yan LI ; Wei WANG ; Hai WANG ; He Tao YU ; Zhu BA ; De CHENG ; Le Ping NING ; Chang Liang LUO ; Xiao Song QIN ; Jin ZHANG ; Ning WU ; Hui Jun XIE ; Jina Hua PAN ; Jian SHUI ; Jian WANG ; Jun Ping YANG ; Xing Hui LIU ; Feng Xia XU ; Lei YANG ; Li Yi HU ; Qun ZHANG ; Biao LI ; Qing Lin LIU ; Man ZHANG ; Shou Jun SHEN ; Min Min JIANG ; Yong WU ; Jin Wei HU ; Shuang Quan LIU ; Da Yong GU ; Xiao Bing XIE
Chinese Journal of Preventive Medicine 2023;57(7):1047-1058
Objective: Compare and analyze the results of the domestic Lanyi AH600 glycated hemoglobin analyzer and other different detection systems to understand the comparability of the detection results of different detectors, and establish the best cut point of Lanyi AH600 determination of haemoglobin A1c (HbA1c) in the diagnosis of diabetes. Methods: Multi center cohort study was adopted. The clinical laboratory departments of 18 medical institutions independently collected test samples from their respective hospitals from March to April 2022, and independently completed comparative analysis of the evaluated instrument (Lanyi AH600) and the reference instrument HbA1c. The reference instruments include four different brands of glycosylated hemoglobin meters, including Arkray, Bio-Rad, DOSOH, and Huizhong. Scatter plot was used to calculate the correlation between the results of different detection systems, and the regression equation was calculated. The consistency analysis between the results of different detection systems was evaluated by Bland Altman method. Consistency judgment principles: (1) When the 95% limits of agreement (95% LoA) of the measurement difference was within 0.4% HbA1c and the measurement score was≥80 points, the comparison consistency was good; (2) When the measurement difference of 95% LoA exceeded 0.4% HbA1c, and the measurement score was≥80 points, the comparison consistency was relatively good; (3) The measurement score was less than 80 points, the comparison consistency was poor. The difference between the results of different detection systems was tested by paired sample T test or Wilcoxon paired sign rank sum test; The best cut-off point of diabetes was analyzed by receiver operating characteristic curve (ROC). Results: The correlation coefficient R2 of results between Lanyi AH600 and the reference instrument in 16 hospitals is≥0.99; The Bland Altman consistency analysis showed that the difference of 95% LoA in Nanjing Maternity and Child Health Care Hospital in Jiangsu Province (reference instrument: Arkray HA8180) was -0.486%-0.325%, and the measurement score was 94.6 points (473/500); The difference of 95% LoA in the Tibetan Traditional Medical Hospital of TAR (reference instrument: Bio-Rad Variant II) was -0.727%-0.612%, and the measurement score was 89.8 points; The difference of 95% LoA in the People's Hospital of Chongqing Liang Jiang New Area (reference instrument: Huizhong MQ-2000PT) was -0.231%-0.461%, and the measurement score was 96.6 points; The difference of 95% LoA in the Taihe Hospital of traditional Chinese Medicine in Anhui Province (reference instrument: Huizhong MQ-2000PT) was -0.469%-0.479%, and the measurement score was 91.9 points. The other 14 hospitals, Lanyi AH600, were compared with 4 reference instrument brands, the difference of 95% LoA was less than 0.4% HbA1c, and the scores were all greater than 95 points. The results of paired sample T test or Wilcoxon paired sign rank sum test showed that there was no statistically significant difference between Lanyi AH600 and the reference instrument Arkray HA8180 (Z=1.665,P=0.096), with no statistical difference. The mean difference between the measured values of the two instruments was 0.004%. The comparison data of Lanyi AH600 and the reference instrument of all other institutions had significant differences (all P<0.001), however, it was necessary to consider whether it was within the clinical acceptable range in combination with the results of the Bland-Altman consistency analysis. The ROC curve of HbA1c detected by Lanyi AH600 in 985 patients with diabetes and 3 423 patients with non-diabetes was analyzed, the area under curve (AUC) was 0.877, the standard error was 0.007, and the 95% confidence interval 95%CI was (0.864, 0.891), which was statistically significant (P<0.001). The maximum value of Youden index was 0.634, and the corresponding HbA1c cut point was 6.235%. The sensitivity and specificity of diabetes diagnosis were 76.2% and 87.2%, respectively. Conclusion: Among the hospitals and instruments currently included in this study, among these four hospitals included Nanjing Maternity and Child Health Care Hospital in Jiangsu Province (reference instrument: Arkray HA8180), Tibetan Traditional Medical Hospital of TAR (reference instrument: Bio-Rad Variant Ⅱ), the People's Hospital of Chongqing Liang Jiang New Area (reference instrument: Huizhong MQ-2000PT), and the Taihe Hospital of traditional Chinese Medicine in Anhui Province (reference instrument: Huizhong MQ-2000PT), the comparison between Lanyi AH600 and the reference instruments showed relatively good consistency, while the other 14 hospitals involved four different brands of reference instruments: Arkray, Bio-Rad, DOSOH, and Huizhong, Lanyi AH600 had good consistency with its comparison. The best cut point of the domestic Lanyi AH600 for detecting HbA1c in the diagnosis of diabetes is 6.235%.
Pregnancy
;
Child
;
Humans
;
Female
;
Glycated Hemoglobin
;
Cohort Studies
;
Diabetes Mellitus/diagnosis*
;
Sensitivity and Specificity
;
ROC Curve

Result Analysis
Print
Save
E-mail